Gene Biotherapeutics (Gene Biotherapeutics) Other Net Income (Loss) : $0.00 Mil (TTM As of Dec. 2020)

View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Other Net Income (Loss)?

Gene Biotherapeutics's Other Net Income (Loss) for the three months ended in Dec. 2020 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2020 was $0.00 Mil.

Gene Biotherapeutics's quarterly Other Net Income (Loss) increased from Jun. 2020 ($0.00 Mil) to Sep. 2020 ($0.00 Mil) but then declined from Sep. 2020 ($0.00 Mil) to Dec. 2020 ($0.00 Mil).

Gene Biotherapeutics's annual Other Net Income (Loss) declined from Dec. 2018 ($0.00 Mil) to Dec. 2019 ($0.00 Mil) but then stayed the same from Dec. 2019 ($0.00 Mil) to Dec. 2020 ($0.00 Mil).

Gene Biotherapeutics Other Net Income (Loss) Historical Data

The historical data trend for Gene Biotherapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Other Net Income (Loss) Chart

Gene Biotherapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Other Net Income (Loss)

Get a 7-Day Free Trial

Gene Biotherapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Gene Biotherapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gene Biotherapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121

Website

https://www.genebiotherapeutics.com

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.

Executives

Andrew M Leitch	director	6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison	director	C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy	officer: Chief Financial Officer
Ronald I Simon	other: Former Director	485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten	director, officer: PRESIDENT and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines

From GuruFocus

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Baron Funds Comments on CarMax Inc.

By Holly LaFon • 02-06-2013

Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation

By PRNewswire PRNewswire • 09-05-2018